2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1588

Disease Activity and Dysregulated Iron Metabolism: A Potentially Overlooked Mechanism for Anaemia in Patients with Systemic Lupus Erythematosus?

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1726

Disease Activity and Health Care Utilization Among Young Adults with Childhood-onset Lupus Transitioning to Adult Care: Follow-Up Data from the Pediatric Lupus Outcomes Study

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1725

Disease Activity in Childhood-Onset Systemic Lupus Erythematosus: Initial Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1699

Disease Course of Behçet’s Syndrome Patients Not Fulfilling International Study Group Criteria at Presentation

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

9:00AM-11:00AM: Abstract Number: 1724

Disease Manifestations and Impact on Quality of Life in Subjects with Pre-Pubertal Onset Systemic Lupus Erythematosus

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Abstract Number: 972

Disease Severity Is Linked to an Increase in Autoantibody Diversity in IgG4-related Disease

B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 1057

Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1038

Distinct Cell-bound Complement Activation Signatures Are Observed in Patients with Systemic Lupus Erythematosus

SLE – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 1711

Distinctive Imaging Features Between IgG4-Related Ophthalmic Disease and Graves’ Orbitopathy: A Comparative Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

9:00AM-11:00AM: Abstract Number: 1465

Diversity Analysis of Intestinal Flora in Patients with Sjogren’s Syndrome

Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1030

DNA Methylation Changes Are Associated with Particulate Matter 2.5 Exposure in SLE Patients

SLE – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 1616

Do All Antiphospholipid Antibodies Confer the Same Risk for Major Organ Involvement in Systemic Lupus Erythematosus Patients?

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1230

Do Serum Urate-Associated Genetic Variants Influence Gout Risk in People on Diuretics? Analysis of the UK Biobank

Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

9:00AM-11:00AM: Abstract Number: 1088

Does Drug Effectiveness of 2nd and 3rd TNF Inhibitors in Patients with Psoriatic Arthritis Depend on the Reason for Withdrawal from the Previous Treatment? – Results from the EuroSpA Research Collaboration

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1676

Does Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Prevent Hospitalizations for Other Infections in Vasculitis Patients?

Vasculitis – ANCA-Associated Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].